



Procter & Gamble Hygiene  
and Health Care Limited  
CIN: L24239MH1964PLC012971  
Registered Office:  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
Tel: (91-22) 2826 6000  
Fax: (91-22) 2826 7337  
Website: in.pg.com

**February 1, 2022**

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001  
Ref:- Scrip Code:- 500459

The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai - 400051  
Ref:- Scrip Code:- PGHH

Dear Sir / Madam,

**Sub:- Unaudited Financial Results for the quarter ended December 31, 2021 and Interim Dividend for Financial Year 2021-22**

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended December 31, 2021 were approved.

We are enclosing herewith the following:

- Unaudited Financial Results for the quarter ended December 31, 2021;
- Press Release;
- Limited Review Report in respect of the Unaudited Financial Results for the quarter ended December 31, 2021 furnished by Statutory Auditors of the Company; and

Further, we are pleased to inform you that the Board of Directors of the Company at its meeting held today, inter alia, have declared an Interim Dividend for the Financial Year 2021-22 of Rs. 95 per Equity Share (Face Value of Rs. 10/- each). The dividend shall be paid on or before February 28, 2022.

As informed earlier in our letter dated January 27, 2022, record date for the purpose of eligibility for payment of said Interim Dividend shall be February 9, 2022.

Kindly take the same on record and oblige.

Thanking you.

Yours faithfully,  
For Procter & Gamble Hygiene and Health Care Limited

*Flavia Machado*  
Flavia Machado  
Senior Manager- Legal and Secretarial





STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 31st DECEMBER 2021

Particulars	(1)	(2)	(3)	(4)	(5)	(6)
	Three Months Ended 31st Dec 2021	Preceding Three Months Ended 30th Sept 2021	Corresponding Three Months Ended 31st Dec 2020	Six Months Ended 31st Dec 2021	Corresponding Six Months Ended 31st Dec 2020	Previous Year Ended 30th June 2021
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Revenue from operations	1 09 298	1 05 830	1 01 844	2 15 128	2 02 789	3 57 414
2 Other income	686	580	935	1 266	1 891	3 938
<b>3 Total income (1+2)</b>	<b>1 09 984</b>	<b>1 06 410</b>	<b>1 02 779</b>	<b>2 16 394</b>	<b>2 04 680</b>	<b>3 61 352</b>
<b>4 Expenses</b>						
a) Cost of raw and packing materials consumed	35 944	34 304	29 705	70 248	62 601	1 12 839
b) Purchases of stock-in-trade (Traded goods)	1 167	1 385	804	2 552	1 604	4 113
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	922	( 268)	777	654	1 399	( 1 022)
d) Employee benefits expense	5 991	5 616	4 136	11 607	10 284	20 168
e) Finance costs	294	59	207	353	243	611
f) Depreciation and amortization expense	1 289	1 269	1 198	2 558	2 378	4 766
g) Impairment losses (Refer Note 4)	----	----	----	----	----	764
h) Advertising & sales promotion expenses	13 862	12 336	10 857	26 198	19 877	52 248
i) Other expenses	21 765	22 325	21 324	44 090	38 953	79 876
<b>Total expenses</b>	<b>81 234</b>	<b>77 026</b>	<b>69 008</b>	<b>1 58 260</b>	<b>1 37 339</b>	<b>2 74 363</b>
<b>5 Profit before tax (3-4)</b>	<b>28 750</b>	<b>29 384</b>	<b>33 771</b>	<b>58 134</b>	<b>67 341</b>	<b>86 989</b>
<b>6 Tax expense</b>						
a) Current tax	7 957	7 864	8 893	15 821	17 703	22 873
b) Deferred tax	( 413)	( 309)	( 413)	( 722)	( 667)	( 889)
c) Prior year tax adjustments	----	----	229	----	( 143)	( 174)
<b>7 Profit for the period (5-6)</b>	<b>7 544</b>	<b>7 555</b>	<b>8 709</b>	<b>15 099</b>	<b>16 893</b>	<b>21 810</b>
<b>8 Other comprehensive income</b>						
Items that will not be reclassified to profit or loss:						
Re-measurement of the defined benefit plans	( 202)	45	( 243)	( 157)	( 300)	179
Income tax effect on above	50	( 11)	62	39	76	( 45)
<b>Total other comprehensive income for the period</b>	<b>( 152)</b>	<b>34</b>	<b>( 181)</b>	<b>( 118)</b>	<b>( 224)</b>	<b>134</b>
<b>9 Total comprehensive income for the period (7+8)</b>	<b>21 054</b>	<b>21 863</b>	<b>24 881</b>	<b>42 917</b>	<b>50 224</b>	<b>65 313</b>
10 Paid-up equity share capital (Face Value ₹ 10 per equity share)	3 246	3 246	3 246	3 246	3 246	3 246
11 Other Equity						68 181
<b>12 Earnings per Share (Face value of ₹ 10 per equity share) (not annualised) :</b>						
a) Basic	65.33	67.25	77.21	132.58	155.42	200.79
b) Diluted	65.33	67.25	77.21	132.58	155.42	200.79

See accompanying notes to the financial results

Notes:

1 Statement of Assets and Liabilities

Particulars	As at 31 <sup>st</sup> Dec 2021 (Unaudited)	As at 30 <sup>th</sup> June 2021 (Audited)
	<b>Assets</b>	
<b>Non-current assets</b>		
Property, plant and equipment	16 703	18 381
Capital work-in-progress	3 371	3 758
Financial assets		
(i) Loans	3 783	3 799
Deferred tax assets (Net)	4 563	3 802
Non-current tax assets (Net)	14 393	15 123
Other non-current assets	5 560	6 673
<b>Total non-current assets</b>	<b>48 373</b>	<b>51 536</b>
<b>Current assets</b>		
Inventories	25 480	24 930
Financial assets		
(i) Trade receivables	21 509	14 235
(ii) Cash and cash equivalents	98 772	64 767
(iii) Bank balances other than (ii) above	1 455	1 257
(iv) Loans	641	574
(v) Other financial assets	1 332	2 520
Other current assets	4 031	3 452
	<b>1 53 220</b>	<b>1 11 735</b>
Non current assets held for sale	----	----
<b>Total current assets</b>	<b>1 53 220</b>	<b>1 11 735</b>
<b>Total assets</b>	<b>2 01 593</b>	<b>1 63 271</b>
<b>Equity and liabilities</b>		
<b>Equity</b>		
Equity share capital	3 246	3 246
Other equity	85 720	68 181
<b>Total equity</b>	<b>88 966</b>	<b>71 427</b>
<b>Non-current liabilities</b>		
Financial liabilities		
(i) Other financial liabilities	8	18
Provisions	8 921	8 280
<b>Total non-current liabilities</b>	<b>8 929</b>	<b>8 298</b>
<b>Current liabilities</b>		
Financial liabilities		
(i) Trade payables		
Dues to micro and small enterprises	2 395	1 255
Dues to others	92 085	74 155
(ii) Other financial liabilities	2 767	3 599
Provisions	754	500
Current tax liabilities (Net)	1 064	705
Other current liabilities	4 633	3 332
<b>Total current liabilities</b>	<b>1 03 698</b>	<b>83 546</b>
<b>Total liabilities</b>	<b>1 12 627</b>	<b>91 844</b>
<b>Total equity and liabilities</b>	<b>2 01 593</b>	<b>1 63 271</b>

## 2 Cash Flow Statement

Particulars	Half Year Ended 31 <sup>st</sup> Dec 2021 (Unaudited)	Year Ended 30 <sup>th</sup> June 2021 (Audited)
<b>A. Cash Flows from Operating Activities</b>		
Profit before tax	58 134	86 989
Adjustments for:		
Depreciation and amortization expense	2 558	4 766
Loss on disposal of property, plant and equipment	53	185
Finance costs	353	593
Allowance for doubtful receivables (Net of recovery)	( 8)	( 112)
Interest income	( 1 212)	( 3 097)
Impairment losses	----	764
Net foreign exchange loss / (gain)	( 211)	( 140)
Expense recognised in respect of equity settled share based payments	591	695
<b>Operating profit before working capital changes</b>	<b>60 258</b>	<b>90 643</b>
<b>Working capital adjustments</b>		
(Increase) / decrease in trade and other receivables	( 7 301)	2 538
Decrease in financial assets	1 125	97
(Increase) in inventories	( 550)	( 4 425)
Decrease / (increase) in other assets	534	( 1 326)
Increase in trade and other payables	20 617	23 542
Increase in provisions	498	583
<b>Cash generated from operations</b>	<b>75 181</b>	<b>1 11 652</b>
Income taxes paid	( 14 732)	( 25 340)
<b>Net cash generated from operating activities</b>	<b>60 449</b>	<b>86 312</b>
<b>B. Cash Flows from Investing Activities</b>		
Interest received	1 224	3 056
Payment to acquire property, plant and equipment	( 1 499)	( 3 160)
Proceeds from sale of property, plant and equipment	----	14
Changes in earmarked balances	----	784
<b>Net cash (used in) / generated from investing activities</b>	<b>( 275)</b>	<b>694</b>
<b>C. Cash Flows from Financing Activities</b>		
Dividend and dividend tax paid	( 25 969)	( 1 10 367)
Principal payment of lease liabilities	( 87)	( 157)
Interest paid on lease liabilities	( 2)	( 18)
Interest paid other than on lease liabilities	( 111)	( 101)
<b>Net cash (used in) financing activities</b>	<b>( 26 169)</b>	<b>( 1 10 643)</b>
<b>Net increase / (decrease) in cash and cash equivalents</b>	<b>34 005</b>	<b>( 23 637)</b>
Cash and cash equivalents at the beginning of the year	64 767	88 404
<b>Cash and cash equivalents at the end of the year</b>	<b>98 772</b>	<b>64 767</b>

- 3 The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 1, 2022 and have been subjected to a limited review by the Statutory Auditors of the Company.
- 4 During the previous year ended June 30, 2021, Non-Current Assets Held for Sale were fully impaired on a conservative basis since the Company was unable to dispose off the said assets. Consequently, an impairment loss amounting to ₹ 764 lakhs was recognized in the Statement of Profit and Loss for the previous year. These assets continue to be classified as held for sale as at December 31, 2021, since the management intends to dispose off these assets and is actively pursuing the said matter.
- 5 The Company has identified Health and Hygiene Products as its single primary reportable segment in accordance with the requirements of Ind AS 108 - Operating Segments. Accordingly, no separate segment information has been provided.
- 6 The Board of Directors at its meeting held on 1st February, 2022 has declared for the current year an interim dividend of ₹ 95 per equity share of face value ₹ 10 each aggregating to ₹ 30 838 lakhs.
- 7 Previous period figures have been regrouped / reclassified wherever necessary.

For and on behalf of the Board of Directors of  
Procter & Gamble Hygiene and Health Care Limited

MADHUSU Digitally signed by  
DAN MADHUSUDAN  
GOPALAN  
GOPALAN Date: 2022.02.01  
16:25:31 +05'30'

Madhusudan Gopalan  
Managing Director

Place: Mumbai  
Date: February 1, 2022



**Procter & Gamble Hygiene and Health Care Limited**  
CIN: L24239MH1964PLC012971  
Registered Office:  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai - 400099  
Tel: (91-22) 2826 6000  
Fax: (91-22) 2826 7337  
Website: [in.pg.com](http://in.pg.com)

## **Procter & Gamble Hygiene and Health Care Ltd. announces second quarter results**

*Sales up 7% for the quarter ended December 31, 2021*

**Mumbai, February 1, 2022:** Procter & Gamble Hygiene and Health Care Ltd. announced today its financial results for the quarter ended December 31, 2021. The company delivered sales of ₹1093 crores, up 7% vs year ago behind the strength of its trusted product portfolio and strong retail execution. Profit After Tax (PAT) was ₹212 crores, down 15% vs year ago due to lower advertising and promotion investments on brand building in the base period due to the pandemic and commodity cost inflation. For the quarter, both Feminine Care and Health Care businesses grew ahead of their categories. Compared to the corresponding quarter two years ago, prior to the pandemic, company sales are up 27% and profit is up 56%.

**Madhusudan Gopalan, Managing Director, Procter & Gamble Hygiene and Health Care Ltd.** said, *“In a challenging market environment, we have delivered strong sales growth behind strong brand fundamentals and improved market execution. As the industry faces commodity inflation challenges, we continue to focus on improving productivity by leveraging advertising and promotion analytics, strengthening our product mix and driving supply chain efficiency to drive balanced top and bottom-line growth. We will continue to focus on our strategy of driving superiority and productivity, invest in brand building, enabled by the strength of our organization and culture.”*

The company’s feminine care brand Whisper continues to step up to raise awareness about menstrual hygiene education. Through its ‘Whisper Menstrual Health & Hygiene Program’, the brand educates more than 90 lakh girls annually on menstrual hygiene. Whisper has also committed to educate 2.5 crore+ adolescent girls on puberty and hygiene over the next three years. In addition, through its 'Period of Pride' campaign, Whisper is advocating for menstrual hygiene to be a part of school curriculum. Whisper is developing this module in partnership with UNESCO and more than 10 lakh people have signed the petition for this endeavor. As part of the company’s COVID-19 relief and response program #PGSurakshaIndia program, the company continues to extend its support to communities through the donation of in-house manufactured masks and sanitizers to combat the spread of COVID-19.

The Board of Directors declared an interim dividend of ₹ 95 on every equity share of ₹10. The record date for the dividend will be February 9, 2022.

### **About Procter & Gamble Hygiene and Health Care Ltd.**

Procter & Gamble Hygiene and Health Care Ltd. (PGHHCL) is one of India’s fastest growing FMCG companies that has in its portfolio Whisper– India’s leading Feminine Hygiene brand, and Vicks – India’s No. 1 Health Care brand and Old Spice. The company has carved a reputation for delivering superior products to meet the needs of consumers. PGHHCL is committed to making every day in the lives of Indian consumers better through the quality of its products and the sincerity of its service. Please visit [in.pg.com](http://in.pg.com) for the latest news.

**For details contact: Madison Public Relations: Malika Bhavnani +91 9820496099; [malika.bhavnani@madisonpr.in](mailto:malika.bhavnani@madisonpr.in)**

# KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

---

**REVIEW REPORT TO  
THE BOARD OF DIRECTORS  
PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED** ("the Company") for the quarter and half year ended December 31, 2021, together with the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, (initialled by us for identification). This Statement, which is the responsibility of the Company's Management, has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 1, 2022, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For KALYANIWALLA & MISTRY LLP  
CHARTERED ACCOUNTANTS**

Firm Reg. No.: 104607W / W100166



*Roshni R. Marfatia*

**PARTNER**

M. No.: 106548

UDIN: 22106548AAAAAR1249

Mumbai, February 1, 2022.

LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001  
TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 31st DECEMBER 2021

(₹ in Lakhs)

Particulars	(1)	(2)	(3)	(4)	(5)	(6)
	Three Months Ended 31st Dec 2021 (Unaudited)	Preceding Three Months Ended 30th Sept 2021 (Unaudited)	Corresponding Three Months Ended 31st Dec 2020 (Unaudited)	Six Months Ended 31st Dec 2021 (Unaudited)	Corresponding Six Months Ended 31st Dec 2020 (Unaudited)	Previous Year Ended 30th June 2021 (Audited)
1 Revenue from operations	1 09 298	1 05 830	1 01 844	2 15 128	2 02 789	3 57 414
2 Other income	686	580	935	1 266	1 891	3 938
<b>3 Total income (1+2)</b>	<b>1 09 984</b>	<b>1 06 410</b>	<b>1 02 779</b>	<b>2 16 394</b>	<b>2 04 680</b>	<b>3 61 352</b>
<b>4 Expenses</b>						
a) Cost of raw and packing materials consumed	35 944	34 304	29 705	70 248	62 601	1 12 839
b) Purchases of stock-in-trade (Traded goods)	1 167	1 385	804	2 552	1 604	4 113
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	922	( 268)	777	654	1 399	( 1 022)
d) Employee benefits expense	5 991	5 616	4 136	11 607	10 284	20 168
e) Finance costs	294	59	207	353	243	611
f) Depreciation and amortization expense	1 289	1 269	1 198	2 558	2 378	4 766
g) Impairment losses (Refer Note 4)	---	---	---	---	---	764
h) Advertising & sales promotion expenses	13 862	12 336	10 857	26 198	19 877	52 248
i) Other expenses	21 765	22 325	21 324	44 090	38 953	79 876
<b>Total expenses</b>	<b>81 234</b>	<b>77 026</b>	<b>69 008</b>	<b>1 58 260</b>	<b>1 37 339</b>	<b>2 74 363</b>
<b>5 Profit before tax (3-4)</b>	<b>28 750</b>	<b>29 384</b>	<b>33 771</b>	<b>58 134</b>	<b>67 341</b>	<b>86 989</b>
<b>6 Tax expense</b>						
a) Current tax	7 957	7 864	8 893	15 821	17 703	22 873
b) Deferred tax	( 413)	( 309)	( 413)	( 722)	( 667)	( 889)
c) Prior year tax adjustments	---	---	229	---	( 143)	( 174)
	<b>7 544</b>	<b>7 555</b>	<b>8 709</b>	<b>15 099</b>	<b>16 893</b>	<b>21 810</b>
<b>7 Profit for the period (5-6)</b>	<b>21 206</b>	<b>21 829</b>	<b>25 062</b>	<b>43 035</b>	<b>50 448</b>	<b>65 179</b>
<b>8 Other comprehensive income</b>						
Items that will not be reclassified to profit or loss:						
Re-measurement of the defined benefit plans	( 202)	45	( 243)	( 157)	( 300)	179
Income tax effect on above	50	( 11)	62	39	76	( 45)
<b>Total other comprehensive income for the period</b>	<b>( 152)</b>	<b>34</b>	<b>( 181)</b>	<b>( 118)</b>	<b>( 224)</b>	<b>134</b>
<b>9 Total comprehensive income for the period (7+8)</b>	<b>21 054</b>	<b>21 863</b>	<b>24 881</b>	<b>42 917</b>	<b>50 224</b>	<b>65 313</b>
10 Paid-up equity share capital (Face Value ₹ 10 per equity share)	3 246	3 246	3 246	3 246	3 246	3 246
11 Other Equity	---	---	---	---	---	68 181
<b>12 Earnings per Share (Face value of ₹ 10 per equity share) (not annualised):</b>						
a) Basic	65.33	67.25	77.21	132.58	155.42	200.79
b) Diluted	65.33	67.25	77.21	132.58	155.42	200.79

See accompanying notes to the financial results

Notes:

1 Statement of Assets and Liabilities

Particulars	As at 31 <sup>st</sup> Dec 2021 (Unaudited)	As at 30 <sup>th</sup> June 2021 (Audited)
	<b>Assets</b>	
<b>Non-current assets</b>		
Property, plant and equipment	16 703	18 381
Capital work-in-progress	3 371	3 758
Financial assets		
(i) Loans	3 783	3 799
Deferred tax assets (Net)	4 563	3 802
Non-current tax assets (Net)	14 393	15 123
Other non-current assets	5 560	6 673
<b>Total non-current assets</b>	<b>48 373</b>	<b>51 536</b>
<b>Current assets</b>		
Inventories	25 480	24 930
Financial assets		
(i) Trade receivables	21 509	14 235
(ii) Cash and cash equivalents	98 772	64 767
(iii) Bank balances other than (ii) above	1 455	1 257
(iv) Loans	641	574
(v) Other financial assets	1 332	2 520
Other current assets	4 031	3 452
	<b>1 53 220</b>	<b>1 11 735</b>
Non current assets held for sale	---	---
<b>Total current assets</b>	<b>1 53 220</b>	<b>1 11 735</b>
<b>Total assets</b>	<b>2 01 593</b>	<b>1 63 271</b>
<b>Equity and liabilities</b>		
<b>Equity</b>		
Equity share capital	3 246	3 246
Other equity	85 720	68 181
<b>Total equity</b>	<b>88 966</b>	<b>71 427</b>
<b>Non-current liabilities</b>		
Financial liabilities		
(i) Other financial liabilities	8	18
Provisions	8 921	8 280
<b>Total non-current liabilities</b>	<b>8 929</b>	<b>8 298</b>
<b>Current liabilities</b>		
Financial liabilities		
(i) Trade payables		
Dues to micro and small enterprises	2 395	1 255
Dues to others	92 085	74 155
(ii) Other financial liabilities	2 767	3 599
Provisions	754	500
Current tax liabilities (Net)	1 064	705
Other current liabilities	4 633	3 332
<b>Total current liabilities</b>	<b>1 03 698</b>	<b>83 546</b>
<b>Total liabilities</b>	<b>1 12 627</b>	<b>91 844</b>
<b>Total equity and liabilities</b>	<b>2 01 593</b>	<b>1 63 271</b>



## 2 Cash Flow Statement

Particulars	Half Year Ended 31 <sup>st</sup> Dec 2021 (Unaudited)	Year Ended 30 <sup>th</sup> June 2021 (Audited)
<b>A. Cash Flows from Operating Activities</b>		
Profit before tax	58 134	86 989
Adjustments for:		
Depreciation and amortization expense	2 558	4 766
Loss on disposal of property, plant and equipment	53	185
Finance costs	353	593
Allowance for doubtful receivables (Net of recovery)	( 8)	( 112)
Interest income	( 1 212)	( 3 097)
Impairment losses	---	764
Net foreign exchange loss / (gain)	( 211)	( 140)
Expense recognised in respect of equity settled share based payments	591	695
<b>Operating profit before working capital changes</b>	<b>60 258</b>	<b>90 643</b>
Working capital adjustments		
(Increase) / decrease in trade and other receivables	( 7 301)	2 538
Decrease in financial assets	1 125	97
(Increase) in inventories	( 550)	( 4 425)
Decrease / (increase) in other assets	534	( 1 326)
Increase in trade and other payables	20 617	23 542
Increase in provisions	498	583
<b>Cash generated from operations</b>	<b>75 181</b>	<b>1 11 652</b>
Income taxes paid	( 14 732)	( 25 340)
<b>Net cash generated from operating activities</b>	<b>60 449</b>	<b>86 312</b>
<b>B. Cash Flows from Investing Activities</b>		
Interest received	1 224	3 056
Payment to acquire property, plant and equipment	( 1 499)	( 3 160)
Proceeds from sale of property, plant and equipment	---	14
Changes in earmarked balances	---	784
<b>Net cash (used in) / generated from investing activities</b>	<b>( 275)</b>	<b>694</b>
<b>C. Cash Flows from Financing Activities</b>		
Dividend and dividend tax paid	( 25 969)	( 1 10 367)
Principal payment of lease liabilities	( 87)	( 157)
Interest paid on lease liabilities	( 2)	( 18)
Interest paid other than on lease liabilities	( 111)	( 101)
<b>Net cash (used in) financing activities</b>	<b>( 26 169)</b>	<b>( 1 10 643)</b>
<b>Net increase / (decrease) in cash and cash equivalents</b>	<b>34 005</b>	<b>( 23 637)</b>
Cash and cash equivalents at the beginning of the year	64 767	88 404
<b>Cash and cash equivalents at the end of the year</b>	<b>98 772</b>	<b>64 767</b>

- 3 The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 1, 2022 and have been subjected to a limited review by the Statutory Auditors of the Company.
- 4 During the previous year ended June 30, 2021, Non-Current Assets Held for Sale were fully impaired on a conservative basis since the Company was unable to dispose off the said assets. Consequently, an impairment loss amounting to ₹ 764 lakhs was recognized in the Statement of Profit and Loss for the previous year. These assets continue to be classified as held for sale as at December 31, 2021, since the management intends to dispose off these assets and is actively pursuing the said matter.
- 5 The Company has identified Health and Hygiene Products as its single primary reportable segment in accordance with the requirements of Ind AS 108 - Operating Segments. Accordingly, no separate segment information has been provided.
- 6 The Board of Directors at its meeting held on 1st February, 2022 has declared for the current year an interim dividend of ₹ 95 per equity share of face value ₹ 10 each aggregating to ₹ 30 838 lakhs.
- 7 Previous period figures have been regrouped / reclassified wherever necessary.

For and on behalf of the Board of Directors of  
Procter & Gamble Hygiene and Health Care Limited

MADHUSU Digitally signed by  
MADHUSUDAN  
DAN  
GOPALAN  
Date: 2022.02.01  
16:25:31 +05'30'

Madhusudan Gopalan  
Managing Director

Place: Mumbai  
Date: February 1, 2022

